Boston Scientific Corp (WBO:BSXC)
€ 86 0 (0%) Market Cap: 126.98 Bil Enterprise Value: 135.61 Bil PE Ratio: 74.26 PB Ratio: 6.39 GF Score: 70/100

Boston Scientific Corp at UBS Global Healthcare Conference (Virtual) Transcript

May 19, 2020 / 01:10PM GMT
Release Date Price: €33 (-1.70%)
Matthew Charles Taylor
UBS Investment Bank, Research Division - Equity Research Analyst of Medical Supplies & Devices

Great. Good morning. Thanks, everybody, for joining us this morning for our next presentation in the virtual med tech track here at the UBS Healthcare Conference. I'm Matt Taylor. UBS' U.S. medical supplies and devices analyst. And I'm really pleased to be joined by management from Boston Scientific. We have a few members of the management team on the line today: Susie Lisa from Investor Relations; Lauren Tengler also Director of IR; and we have Jeff Mirviss, who's the EVP and President of the Peripheral Interventions Group, along with Dr. Michael Jaff, who's the VP of Clinical Affairs, Innovation and Technology for the group as well. So this should be a good opportunity to talk both about COVID management, but also focus on the peripheral group, which has really got a lot of exciting product launches coming down the pipe that we'll talk about.

Just one piece of orientation for the call. If you're not familiar with the format yet. This will be about a 40-minute Q&A

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot